The immunotherapy drug first earned FDA approval to treat urothelial carcinoma — the most common type of bladder cancer — in May 2016. The FDA also approved the drug as a second-line treatment for metastatic non-small cell lung cancer in October 2016.
Tecentriq can now be used to treat patients with advanced bladder cancer who are not eligible for standard chemotherapy, according to the report.
More articles on supply chain:
Medtronic sells majority of medical supplies unit to Cardinal for $6.1B
Bristol-Myers will license drugs to Biogen, Roche for $470M
FDA rejects Eli Lilly’s arthritis drug
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.